


Figure e-1. NfL and p/t-tau ratio levels by suspected pathology.



(A) NfL levels and (B) the p/t-tau ratio in patients with suspected FTLD-TDP or FTLD-tau pathology. Patients with suspected pathology [Clinical PSP (green hexagons) in FTLD-tau group; clinical FTD-MND (grey downward triangle) and clinical svPPA (blue filled hexagon) in FTLD-TDP-43 group] were combined in this analysis with those with known underlying pathology [FTLD-tau pathology (blue circles); *MAPT* mutation (filled light-purple squares); PSP pathology (red squares); CBD pathology (grey filled upward triangles); FTLD-TDP pathology (acqua upward triangles); *GRN* mutation (filled blue downward triangles); *C9orf72* repeat expansion (purple filled diamonds); *OPTN* mutation (green diamonds)]. Horizontal lines represent medians.

The median of p-tau levels in suspected FTLD-TDP pathology was 39 pg/ml (interquartile range 33-49) and 38 pg/ml (30-49) in suspected FTLD-tau pathology; median t-tau level was 352 pg/ml (271-471) for suspected FTLD-TDP, and 267 pg/ml (177-353) for suspected FTLD-tau pathology.

***: $p < 0.001$; CBD: corticobasal degeneration; CSF: cerebrospinal fluid; FTD-MND:

frontotemporal dementia with concomitant motor neuron disease; FTLD-tau: frontotemporal

lobar degeneration with tau inclusions; FTLD-TDP: frontotemporal lobar degeneration with

TAR DNA-binding protein 43 inclusions; NfL: neurofilament light chain; n.s.: not significant;

PSP: progressive supranuclear palsy; svPPA: semantic variant primary progressive aphasia.